In February 2019, the European Parliament passed a decision on cannabis use for medical purposes. A distinction is made between medical hemp (Cannabis sativa) and marijuana (Cannabis Indica). These two varieties differ mainly in the amount of the content of the psychoactive substance THC (Delta-9-tetrahydrocannabinol): In hemp, their content is up to 0.3%, in marijuana over 10%. The basic psychoactive ingredient in marijuana THC is intoxicating, stimulates appetite and relieves symptoms such as pain and nausea; In hemp, it is CBD (Cannabidiol), a non-psychoactive compound that is known to relieve anxiety, pain, inflammation, protect neurons, and is responsible for the recovery from stress, body resistance, and the ability to defend against harmful external influences. So, CBD is not a cure, but it creates the conditions for the human body to fight disease.
The cultivation of hemp requires approval from the Ministry of Agriculture. In addition, cultivation and processing plants for medical hemp must be designed in accordance with the requirements of the GACP Good Agricultural and Collection Practice of the EU and the Good Manufacturing Practice (GMP). If the THC content in hemp exceeds 0.3%, it must be destroyed.
The FormaPharm Engineering Group was involved in the creation of the technical project documentation for the conception of the construction of a factory for growing, producing and packaging cannabis for medical purposes in accordance with GMP standards. The area for growing and processing cannabis in this factory is approximately 2300 m2. The annual capacity of the factory is 2600 kg of dried cannabis flowers.